Terbinol tablets

Form: Tablets
Dosage: 250mg
Packaging: 14 tablets

Active substance :  terbinafine

Form : tablets (breakable)

Dosage : 250 mg  terbinafine per tablet

Packaging : Box containing  1 blister of 14 tablets

Target : Adults, adolescents et children (>2 y of age)

Fungal infections of the skin and hair, caused by

  • Dermatophytes (scalp ringworm – tinea corporis, tinea cruris, tinea pedis)
  • Fungal infections of the nails: onychomycosis induced by dermatophytes.

Adults and children over the age of two

1 tablet 250 mg once daily

Paediatric population

Children over 2 years (>12kg):

  • For children weighing less than 20kg: 62.5mg/day (1/4 tablet)
  • For children weighing 20-40kg: 125mg (= half a 250mg tablet), once daily.
  • For children weighing more than 40 kg: 1 x 250 mg tablet, once a day.

The duration of treatment varies according to the indication and severity of the infection:

  • Skin infections: 1 to 2 weeks. Complete disappearance of the signs and symptoms of the infection occurs several weeks after the mycological cure.
  • Hair and scalp infections (Tinea capitis): 4 weeks
  • Onychomycosis:
    • Toenails: up to 12 weeks
    • Finger nails: 6 to 16 weeks

The full clinical effect is only observed a few months after stopping the treatment. This period corresponds to the time needed for a healthy nail to grow.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma